Publications by authors named "Satoshi Hamauchi"

Claim this Profile
L
Long-term administration of multikinase inhibitors is a potential risk factor for atherosclerosis in patients with thyroid cancer.
Nao Muraoka, Takuya Oyakawa, Ayano Fujita, Kei Iida, Satoshi Hamauchi

Cardiology· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multimodal treatments for patients with locally advanced synchronous esophageal and head and neck cancer.
Satoshi Suzuki, Tomoya Yokota, Akifumi Notsu, Satoshi Hamauchi, Kunihiro Fushiki

Int J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment.
Hiroshi Imaoka, Masafumi Ikeda, Masato Ozaka, Kotoe Oshima, Naohiro Okano, Satoshi Hamauchi

Eur J Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal number of needle passes in EUS-guided tissue sampling for genomic profiling: a randomized, noncomparative trial.
Hirotoshi Ishiwatari, Kazuma Ishikawa, Junya Sato, Fumitaka Niiya, Hirofumi Yasui, Satoshi Hamauchi

Gastrointest Endosc· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of ME2136 (Asenapine Maleate) plus standard antiemetic therapy for patients, including diabetic patients, receiving cisplatin-based chemotherapy.
Satoshi Hamauchi, Hirofumi Yasui, Tomoya Yokota, Takahiro Tsushima, Kunihiro Fushiki

Invest New Drugs· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of relative cisplatin dose to skeletal muscle mass on adverse events in patients with head and neck cancer undergoing chemoradiotherapy.
Satoshi Suzuki, Tomoya Yokota, Akifumi Notsu, Satoshi Hamauchi, Yusuke Onozawa

Oncologist· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and safety of anamorelin among patients with diabetes.
Kenju Ando, Tateaki Naito, Satoshi Hamauchi, Keita Miura, Yuichiro Nishibori

Int J Clin Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib rechallenge after failure of lenvatinib and sorafenib in metastatic thyroid cancer.
Tomoya Yokota, Satoshi Hamauchi, Takeshi Kawakami, Kunihiro Fushiki

Invest New Drugs· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world data of anamorelin in advanced gastrointestinal cancer patients with cancer cachexia.
Ari Nishimura, Satoshi Hamauchi, Akifumi Notsu, Kunihiro Fushiki, Kotoe Oshima

BMC Palliat Care· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study.
Hiroya Taniguchi, Kentaro Yamazaki, Toshiki Masuishi, Takeshi Kawakami, Yusuke Onozawa, Satoshi Hamauchi

Oncologist· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic medicine in companion diagnostics of germline BRCA testing of Japanese pancreatic cancer patients.
Hiroyuki Matsubayashi, Akiko Todaka, Takeshi Kawakami, Satoshi Hamauchi, Tomoya Yokota

J Hum Genet· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin.
Takeshi Kawakami, Akiko Todaka, Kotoe Oshima, Kunihiro Fushiki, Satoshi Hamauchi

BMC Cancer· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and safety of gemcitabine plus nab-paclitaxel in elderly patients with advanced pancreatic cancer: a single-center retrospective cohort study.
Sae Ohwada, Akiko Todaka, Hiroshi Nakase, Hiromichi Shirasu, Takeshi Kawakami, Satoshi Hamauchi

Invest New Drugs· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of the number of metastatic lymph nodes after surgery in locally advanced hypopharyngeal cancer.
Ari Nishimura, Tomoya Yokota, Satoshi Hamauchi, Yusuke Onozawa, Akifumi Notsu

BMC Cancer· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunological and Genetic Characterization of Patients With Head and Neck Cancer who Developed Recurrence.
Kazuaki Yasui, Ryota Kondou, Haruo Miyata, Akira Iizuka, Tadashi Ashizawa, Satoshi Hamauchi

Anticancer Res· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3 Randomized Trial of Topical Steroid Versus Placebo for Prevention of Radiation Dermatitis in Patients With Head and Neck Cancer Receiving Chemoradiation.
Tomoya Yokota, Sadamoto Zenda, Ichiro Ota, Tomoko Yamazaki, Takuhiro Yamaguchi, Satoshi Hamauchi

Int J Radiat Oncol Biol Phys· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer.
Hiroto Inoue, Akiko Todaka, Kentaro Yamazaki, Kunihiro Fushiki, Hiromichi Shirasu, Satoshi Hamauchi

Invest New Drugs· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incurable locoregional disease is a strong poor prognostic factor in recurrent or metastatic squamous cell carcinoma of the head and neck.
Ari Nishimura, Tomoya Yokota, Satoshi Hamauchi, Yusuke Onozawa, Hiromichi Shirasu

Int J Clin Oncol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triplet induction chemotherapy followed by less invasive surgery without reconstruction for human papillomavirus-associated oropharyngeal cancers: Why is it successful or unsuccessful?
Tomoya Yokota, Tetsuro Onitsuka, Satoshi Hamauchi, Hiromichi Shirasu, Yusuke Onozawa

Int J Clin Oncol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A retrospective cohort study to investigate the incidence of cancer-related weight loss during chemotherapy in gastric cancer patients.
Masaru Fukahori, Masayuki Shibata, Satoshi Hamauchi, Eiji Kasamatsu, Koji Machii

Support Care Cancer· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Retrospective Cohort Study to Investigate the Incidence of Cachexia During Chemotherapy in Patients with Colorectal Cancer.
Masayuki Shibata, Masaru Fukahori, Eiji Kasamatsu, Koji Machii, Satoshi Hamauchi

Adv Ther· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unresectable head and neck cancer patients ineligible for combination treatment with docetaxel, cisplatin, and 5-fluorouracil.
Hiromichi Shirasu, Tomoya Yokota, Takeshi Kawakami, Satoshi Hamauchi, Yusuke Onozawa

Int J Clin Oncol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility and efficacy of chemoradiotherapy with concurrent split-dose cisplatin after induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for locally advanced head and neck cancer.
Tomoya Yokota, Masayuki Shibata, Satoshi Hamauchi, Hiromichi Shirasu, Yusuke Onozawa

Mol Clin Oncol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemoradiotherapy for high-risk stage II laryngeal cancer.
Satoshi Hamauchi, Tomoya Yokota, Yusuke Onozawa, Hirofumi Ogawa, Tsuyoshi Onoe

Int J Clin Oncol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How Should We Approach Locally Advanced Squamous Cell Carcinoma of Head and Neck Cancer Patients Ineligible for Standard Non-surgical Treatment?
Tomoya Yokota, Satoshi Hamauchi, Hiromichi Shirasu, Yusuke Onozawa, Hirofumi Ogawa

Curr Oncol Rep· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis